Brokerages predict that Vascular Biogenics Ltd. (NASDAQ:VBLT) will report earnings per share (EPS) of ($0.10) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Vascular Biogenics’ earnings, with estimates ranging from ($0.12) to ($0.09). Vascular Biogenics reported earnings of ($0.14) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 28.6%. The business is scheduled to issue its next quarterly earnings report on Thursday, August 12th.
On average, analysts expect that Vascular Biogenics will report full year earnings of ($0.46) per share for the current year, with EPS estimates ranging from ($0.56) to ($0.40). For the next year, analysts forecast that the firm will report earnings of ($0.46) per share, with EPS estimates ranging from ($0.55) to ($0.37). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Vascular Biogenics.
Vascular Biogenics (NASDAQ:VBLT) last issued its earnings results on Monday, May 10th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.01. Vascular Biogenics had a negative net margin of 2,692.41% and a negative return on equity of 61.77%.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. PVG Asset Management Corp bought a new position in Vascular Biogenics in the 1st quarter worth approximately $53,000. Bank of New York Mellon Corp acquired a new position in Vascular Biogenics during the 4th quarter worth $47,000. HBK Sorce Advisory LLC acquired a new position in Vascular Biogenics during the 1st quarter worth $44,000. Vident Investment Advisory LLC grew its stake in shares of Vascular Biogenics by 50.0% in the first quarter. Vident Investment Advisory LLC now owns 22,950 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 7,650 shares in the last quarter. Finally, Koshinski Asset Management Inc. bought a new position in shares of Vascular Biogenics in the fourth quarter valued at approximately $421,000. 4.50% of the stock is currently owned by institutional investors.
Shares of NASDAQ:VBLT opened at $1.98 on Tuesday. The company has a market cap of $95.41 million, a PE ratio of -3.47 and a beta of 1.17. Vascular Biogenics has a fifty-two week low of $1.01 and a fifty-two week high of $3.17. The firm has a 50-day simple moving average of $1.95 and a 200 day simple moving average of $1.91.
About Vascular Biogenics
Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.